Drug delivery systems are often developed as bespoke technological solutions for a single molecule, route, indication, or patient group. This custom-build logic can generate highly sophisticated systems, but it also produces long development timelines, repeated formulation work, high translation costs, and limited scalability. As therapeutic pipelines become more diverse, this one-product–one-platform paradigm increasingly constrains the ability of pharmaceutical technology to respond efficiently to emerging clinical needs. The central problem addressed in this article is the absence of a formalised design principle for pharmaceutical modularity. Although modular behaviours can be observed in lipid nanoparticles, polymeric carriers, implantable systems, and three-dimensional printed medicines, these examples have not yet been unified into a coherent theory of reconfigurable delivery platform design. Without such a principle, modularity remains an implicit engineering convenience rather than an explicit pharmaceutical development strategy. This article proposes the Pharmaceutical Modularity Principle as a non-empirical theory for reconfigurable delivery platforms across molecules, diseases, and populations. The principle argues that delivery systems should be architected through a decoupled core-platform structure in which drug-specific, disease-targeting, release-modulating, and population-adaptation functions can be independently designed, validated, and substituted. The goal is not to eliminate product-specific optimisation, but to reduce unnecessary reinvention by defining which delivery functions can remain stable and which should remain reconfigurable. The proposed theory contributes a formal design vocabulary for platform-based pharmaceutical development. It reframes modularity as a disciplined architecture of functional partitioning, interface standardisation, module-level validation, and controlled reconfiguration. Future empirical work will be required to test whether the principle can reduce development time, support regulatory bridging, and enable adaptable product families without compromising quality, safety, or therapeutic performance.
Eurasian Academy of Medicine and Dentistry